 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Biopharmaceutical |
| Founded | 2009 |
| Founder | Arie Belldegrun and Joshua Kazam |
| Fate | Acquired by Gilead Sciences |
| Headquarters | , |
Key people |
|
| Products | Cancer immunotherapy |
Number of employees | 2,000 |
| Parent | Gilead Sciences |
| Website | www.kitepharma.com |
| Footnotes / references Key People,[2][3] Founder[3][1] | |
Kite Pharma is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
- ^ a b "Kite Pharma LEADERSHIP". March 10, 2023. Archived from the original on March 10, 2023. Retrieved March 10, 2023.
- ^ Cite error: The named reference
boardwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Wright2020was invoked but never defined (see the help page).
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search